• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

個別化薬物治療を目指した内因性物質による新規CYP1A2活性評価法の開発

Research Project

Project/Area Number 25K10096
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 47060:Clinical pharmacy-related
Research InstitutionTokyo University of Pharmacy and Life Science

Principal Investigator

横川 彰朋  東京薬科大学, 薬学部, 講師 (70328558)

Project Period (FY) 2025-04-01 – 2028-03-31
Project Status Granted (Fiscal Year 2025)
Budget Amount *help
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2027: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2026: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2025: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Keywords個別化薬物治療 / CYP1A2 / メラトニン
Outline of Research at the Start

CYP1A2は薬物代謝に重要な酵素ですが,その活性には個人差があり,薬の効果や副作用に影響を与えます.本研究では,CYP1A2が代謝する内因性物質メラトニンとその代謝産物の比に注目し,簡便かつ非侵襲的にCYP1A2活性を評価する新規手法の開発を目指します.

URL: 

Published: 2025-04-17   Modified: 2025-06-20  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi